Category Endocrine Mechanisms & Hormone Action


HIV Drug May Slow Down Metastatic Triple-Negative Breast Cancer

Researchers at the Kimmel Cancer Center, led by Dr. Richard G. Pestell have discovered that FDA-approved HIV drugs may stop triple-negative breast cancer from spreading to other organs in pre-clinical models. These results were originally reported in Cancer Research. Recent articles about this discovery have also appeared in NewsWise and the Philadelphia Inquirer.


Stronger Intestinal Barrier May Prevent Cancer in the Rest of the Body, New Study Suggests

A leaky gut may be the root of some cancers forming in the rest of the body, a new study published online Feb. 21 in PLoS ONE by Thomas Jefferson University researchers suggests. It appears that the hormone receptor guanylyl cyclase C (GC-C)—a previously identified tumor suppressor that exists in the intestinal tract—plays a key …


Blocking Receptor in Key Hormone Fires Up Enzyme to Kill Pancreatic Cancer Cells

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division. With that, a new chemopreventive agent that inhibits the …


Dr. Karen Knudsen Receives Ron Ross Award

See the Award Announcement for more information about the Award and its latest recipient. The following was abstracted from the announcement. Dr. Karen Knudsen of the Kimmel Cancer Center received the Ron Ross Award at the 5th Pacific Rim Breast and Prostate Cancer Meeting, held in Kingscliff, Australia, May 3-7, 2011. Dr. Ron Ross was …


Dr. Gomella Appointed to Editorial Council for Urology Times and Mid Atlantic Representative for Scociety for Urology Chairperson and Program Directors

Dr. Leonard Gomella, M.D., F.A.C.S., the Bernard W. Godwin, Jr. Professor of Prostate Cancer, associate director for Clinical Affairs at the Kimmel Cancer Center (KCC) at Jefferson, and Chair of the Department of Urology at Jefferson Medical College of Thomas Jefferson University, has been appointed as a member of the Urology Times Editorial Council. He …


Marker Identifies Breast Cancer Patients Likely to Respond to Tamoxifen

ER positive breast cancer patients whose tumors have active protein Stat5 have increased likelihood of responding to anti-estrogen therapy PHILADELPHIA—Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears …


“Longevity” Protein SIRT1 May Ward Off Precursor to Prostate Cancer

Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the “longevity” protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia (PIN). “Prostate cancer is one of the malignancies that has a …


Loss of the retinoblastoma tumor suppressor pushes prostate cancer into lethal stage, say Kimmel Cancer Center researchers

Their study, the first to uncover a new role for this powerful gene, may lead to clinical “barcoding” of a patient’s prostate cancer to help direct therapy (PHILADELPHIA) – The retinoblastoma tumor suppressor gene (Rb), long thought to protect cells against cancer development, appears to play a very different role in prostate cancer, say scientists …


“How & Why” Cancer Cells Eat Us Alive

Four key studies now propose a new theory about how cancer cells grow and survive, allowing researchers to design better diagnostics and therapies to target high-risk cancer patients.  These studies were conducted by a large team of researchers at Thomas Jefferson University’s Kimmel Cancer Center.


Dr. Leonard G. Gomella Studies the Effect of Dutasteride on the Risk of Prostate Cancer

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …